TransCode Therapeutics, Inc.
Price Action
Technical Summary
DOWNTRENDTransCode Therapeutics, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 22), showing significant lag compared to the market leaders. Earnings contraction of 381% provides fundamental context to the price action. Investors should exercise caution due to high volatility (96% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $8.40 | -4.75% | BELOW |
| 50 SMA | $8.90 | -10.07% | BELOW |
| 100 SMA | $8.91 | -10.18% | BELOW |
| 150 SMA | $9.56 | -16.32% | BELOW |
| 200 SMA | $9.88 | -19.05% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RNAZ in an uptrend right now?
RNAZ has a trend score of 0/4 based on Minervini's Stage Analysis. Currently showing broken structure - 0 of 4 trend criteria are met.
Is RNAZ overbought or oversold?
RNAZ's RSI (14) is 31. The stock is in neutral territory, neither overbought nor oversold.
Is RNAZ outperforming the market?
RNAZ has a Relative Strength (RS) Rating of 22 out of 99. RNAZ is currently lagging the broader market.
Where is RNAZ in its 52-week range?
RNAZ is trading at $8.00, which is 38% of its 52-week high ($20.99) and 13% above its 52-week low ($6.08).
How volatile is RNAZ?
RNAZ has a Beta of 0.95 and 52-week volatility of 96%. It's less volatile than the S&P 500 - generally more stable.